A Multicenter, Randomized, Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection and Decompensated Cirrhosis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 22 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 23 Jun 2017 Planned End Date changed from 1 Apr 2018 to 1 Jun 2018.
- 23 Jun 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Mar 2018.